Neuland Laboratories Ltd (NEULANDLAB) Q1 FY27 Earnings Call: Revenue Surges 117%, Peptide Plant Commissioning Imminent

Neuland Laboratories Ltd held its Q1 FY27 earnings call on August 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Exceptional Quarter with Record Growth

• Total income of Rs.650.1 Cr in Q1 FY 2026-2027 — up 116.9% YoY from Rs.300.6 Cr in Q1 FY 2025-2026, driven by higher revenue, operating leverage, and favorable customer mix.
• EBITDA of Rs.231.1 Cr — margin expanded to 35.5% in Q1 FY 2026-2027, benefiting from favorable exchange rates; management views anything above 25% as a "bonus" and does not expect sustained outperformance.
• Gross margin improved to 61.2% in Q1 FY 2026-2027 from 55.3% in Q1 FY 2025-2026, reflecting a favorable business mix.
• PAT of Rs.147.4 Cr vs. Rs.13.7 Cr in the prior-year quarter; EPS came in at Rs.114.9 per share for Q1 FY 2026-2027.
• Working capital days improved sharply from 137 days at end of FY 2025-2026 to 84 days in Q1 FY 2026-2027, driven by inventory optimization and disciplined execution.
• Management cautioned that quarterly performance will not be even — Q4-to-Q1 sequential comparison is dismissed as Q4 FY26 was an exceptional quarter due to Q3 spillovers.

CDMO Pipeline Strengthens with Larger Molecules

• CDMO growth aspiration of ~20% — management reiterated a long-term target for the segment without providing explicit guidance for FY 2026-2027, citing a strong start to the year.
• Molecule values have increased from ~Rs.50 Cr to potential Rs.500 Cr–Rs.1,000 Cr annually — management cited qualitative customer conversations and larger opportunity sizes as drivers of CDMO pipeline confidence.
• Commercial CDMO growth driven by ~3 molecules — management expects these to drive growth over the next 5–6 years, albeit with quarterly lumpiness.
• One additional commercialization expected in FY 2026-2027 — and possibly one or two in FY 2027-2028, which should increase molecule diversity.
• Development revenue of ~Rs.98 Cr in FY 2025-2026 — down from historical highs of Rs.300 Cr in earlier years; management attributes this to product-specific launch quantities, not a strategic shift.
• No destocking risks are foreseen for FY 2026-2027 — management noted such factors are already incorporated into the order book.

Gland Pharma Sterile API Partnership

• Strategic collaboration with Gland Pharma — announced for niche generic products requiring sterile API manufacturing, leveraging Gland's sterile manufacturing expertise and Neuland's complex API development capabilities.
• No competitive overlap — the partnership is structured as an asset-light arrangement for Neuland, avoiding risks of managing sterile facilities.
• Potential to expand to additional products — management sees the collaboration as a long-term platform beyond the initial product set.
• Partnership demonstrates commitment to specialty CDMO — creating a differentiated platform in sterile APIs and building niche capabilities.

Capacity Investments Accelerate

• Capex cash outflow of Rs.121.6 Cr in Q1 FY 2026-2027 — primarily for new R&D and peptide facilities; additional capex of Rs.203 Cr was approved, with Rs.190 Cr earmarked for capacity expansion at Unit 1.
• Cumulative approved capex over last 13 quarters totals Rs.1,460 Cr — of which Rs.870 Cr has been spent as of Q1 FY 2026-2027.
• Adjacent land acquisition of 6–7 acres at Unit 1 — a short-term capacity strategy to bypass greenfield regulatory cycles, sufficient for the next 2–3 years (through ~FY 2028-29).
• Next phase of capex (FY 2026-2027 and FY 2027-2028) will be "quantitatively higher" — and qualitatively different, potentially including geographic diversification via M&A or organic overseas investments for complex modalities.
• ROCE expected to dip temporarily — management expects a temporary decline during the expansion phase due to capital deployment, but margins are not expected to decline.

Peptide Plant Commissioning Imminent

• Peptide manufacturing plant to be commissioned within a month — in Q2 FY 2026-2027, with confirmed order book visibility and a couple of projects ready to use the facility pre-commissioning.
• Module 1 peptide plant scheduled for commission next month — manufacturing qualification completed, with multiple projects lined up.
• Facility located at an FDA-approved site — management views the new building's FDA audit as a non-gating issue, with an inspection expected in the future based on filing activity.
• Peptide platform relationships maturing — existing customers (5–10 year relationships) are moving from small-scale peptide starting materials to more advanced programs, supporting the higher-value pipeline.
• Substantial commercial revenue from new molecules not anticipated until FY 2027-2028 onwards — development revenue is expected to increase in FY 2026-2027 and will lead to commercial revenue.

Structurally Higher Earning Phase

• Long-term EBITDA margin target of 25%+ — management considers the current margin profile sustainable and referenced earlier guidance of 25% margin (period unspecified) as a reasonable expectation.
• Q1 FY 2026-2027 margin of 35.5% — benefited from favorable exchange rates; management does not expect sustained outperformance above 25%.
• FY 2026-2027 expected to be a year of growth — management reiterated a positive outlook for FY 2026-2027 and FY 2027-2028 without providing specific numeric guidance.
• No material impact from evolving geopolitical environment — management noted no impact on operations, supply chain, or customer commitments to date, but remains vigilant.
• Stock split or bonus is a board matter — management noted it will be discussed following shareholder feedback at the annual meeting.